Aims/hypothesis. Platelet activation, endothelial dysfunction and inflammation may be involved in early stages of diabetic microangiopathy. We therefore investigated patients with Type 1 diabetes mellitus, without (n=19) and with (n=20) microangiopathy, matched for glycaemic control and duration of disease, and matched with healthy control subjects (n=27). Methods. Platelet activation was measured as platelet P-selectin expression using whole blood flow cytometry and as soluble P-selectin by immunoassay. Von Willebrand factor antigen in plasma, serum soluble Eselectin, CD40 ligand (sCD40L) and C-reactive protein (CRP) served as markers for endothelial function and inflammation. Results. Thrombin-induced platelet P-selectin expression was enhanced, and soluble P-selectin and sCD40L concentrations were increased in patients with microangiopathy compared with the control subjects (p<0.01 for both) and with patients without microangiopathy (p<0.05 for P-selectin expression and sP-selectin), whereas all three parameters were similar in patients without microangiopathy and in the control subjects. CRP and soluble E-selectin were increased in patients with microangiopathy, compared with the control subjects (p<0.01 and p<0.05), whereas von Willebrand factor did not differ between the groups. Conclusions/interpretation. Microangiopathy in Type 1 diabetes is associated with platelet hyperactivity, endothelial dysfunction and low-grade inflammation, indicating an increased risk for cardiovascular disease. [Diabetologia (2004) 47:537-540] 
mellitus is at least as great a risk factor for cardiovascular mortality as Type 2 diabetes, and that this also can occur at a young age [2] . Thus, early detection and treatment of risk factors for cardiovascular disease in Type 1 diabetes are warranted.
P-selectin, an adhesion molecule and a constituent of the platelet α-granule membrane and the Weibelpalade bodies in endothelial cells, is expressed on activated platelets and endothelium and is shed into plasma in a soluble form. P-selectin mediates the rolling of monocytes on activated endothelium, induces procoagulant microparticle formation [3] and promotes atherosclerotic lesion development [4] . Increased platelet P-selectin expression and increased plasma concentrations of soluble P-selectin have been reported in diabetes mellitus and in atherosclerotic Diabetes is a strong risk factor for atherothrombotic complications [1] and diabetic vascular complications often begin as microvascular injury. Recently, epidemiological studies have shown that Type 1 diabetes disease, but few studies have focused on the role of Pselectin in Type 1 diabetic microangiopathy.
The CD40-CD40 Ligand (CD40L) system is involved in immune reactions, but could also be an important proinflammatory mediator in atherosclerosis [5] . Interestingly, CD40 is expressed on platelets, and 95% of CD40L in blood is platelet associated. CD40L on activated platelets triggers an inflammatory reaction of endothelial cells [5] and is rapidly shed from the platelets into a biologically active soluble form, sCD40L. Soluble CD40L can be a predictive marker in patients with acute coronary syndromes [6] . One study has reported increased plasma concentrations of sCD40L in Type 1 diabetes, but its relation to vascular complications was not studied [7] .
The aim of this study was to investigate alterations of platelet and endothelial function, as well as inflammatory markers, in diabetic microangiopathy, by comparing well controlled Type 1 diabetic patients with early stages of retinopathy, to patients free from microangiopathy, and healthy control subjects. The patient groups were matched for duration of disease and glycaemic control, the two strongest predictors for developing retinopathy.
Methods

Subjects.
A total of 39 patients with Type 1 diabetes mellitus and with a duration of the disease over 10 years, selected from a register at the Department of Endocrinology and Diabetology at Karolinska Hospital participated in the study. Twenty patients were diagnosed as having microvascular complications. Among these, 13 patients had ophtalmoscopically verified background retinopathy, 6 had non-proliferative retinopathy and 1 had proliferative retinopathy.
Nineteen patients had no history or signs of microvascular complications or cardiovascular disease. Patients with severely impaired metabolic control (HbA 1 c >9.0%) and patients with other concomitant diseases were excluded. The two patient groups were matched for sex, age, duration of disease, metabolic control and BMI. The use of medical treatment (statins, ACE-inhibitors, HRT) was equally distributed among the groups.
The patients were compared with 27 healthy individuals matched for sex and age, recruited among the staff of the hospital. The study was approved by the Ethics Committee of the Karolinska Hospital, and informed consent was obtained from all subjects.
Blood sampling. The subjects were instructed not to take any platelet inhibiting drugs during 14 days preceding the sampling, and to abstain from tobacco and caffeine-containing beverages on the day of the sampling. Blood was collected in the morning after an overnight fast, (before breakfast and morning injection of insulin) after a 30-min rest in a semi-recumbent position. Sampling was done without stasis, using the vacutainer technique.
Blood chemistry analysis. HbA 1 c was measured by an immunoturbidimetric method (TINIA; Roche diagnostics, Mannheim, Germany). Microalbuminuria was analysed using Beckmann IMMAGE Immunochemistry Systems (Beckman Instruments, Richmond, Calif., USA). Enzyme immunoassays (EIA) were used to determine concentrations of sP-selectin, sE-selectin, sCD40L (R&D Systems, Abingdon, UK), and von Willebrand factor antigen (Asserachrom, Diagnostica Stago, France). High sensitivity CRP was determined by means of particle enhanced immunonephelometry (BN Systems, Dade Behring, Marburg, Germany). Urinary 11-dehydro-TxB 2 was analysed using EIA (Cayman Chemical, Ann Arbor, Mich., USA), and a sample work-up procedure developed by us. Thrombin generation was measured as prothrombin fragment 1+2 (Enzygnost F1+2; Behring Diagnostics, Marbourg, Germany) and plasma fibrinogen by the clotting method of Clauss (Diagnostica Stago, Asnieres-sur-Seine, France).
Platelet P-selectin expression. Platelets were identified with a fluorescein isothiocyanate (FITC) conjugated anti-CD42a monoclonal antibody. Platelet P-selectin expression was determined by a R-phycoerythrin (RPE)-conjugated anti-P-selectin monoclonal antibody (Becton Dickinson, San Jose, Calif., USA). FITC and RPE conjugated isotypic monoclonal antibody DAK-GO1 (Dakopatts) were used as negative controls. Agonists used were ADP (1 µmol/l) and thrombin (0.02, 0.03, 0.04, 0.08 IU/ml). When thrombin was used, clotting was prevented by the peptide gly-pro-arg-pro. Within 3 min of collection, 5 µl citrated whole blood was added to 45 µl of Hepesbuffered saline containing antibodies and agonists, and incubated at room temperature for 20 min. Samples were then diluted and fixed with 0.5% formaldehyde saline before analysis using a Coulter EPICS XL-MCL flow cytometer (Coulter, Hialeah, Fla., USA). Platelets were discriminated from other blood cells by their light scattering characteristics and live gated in an electronic bit map. The gated cells were subsequently subjected to single colour analysis of RPE-CD62P fluorescence to obtain the percentage of P-selectin positive cells in the platelet population.
Statistical analysis. Data are expressed as mean ± standard error of the mean, or median and interquartiles. Between-group comparisons were analysed by Student's unpaired two-tailed t test or Mann-Whitney U test. The effects of agonist stimulation were analysed by two factor repeated measures analysis of variance, ANOVA. Correlations were assessed by Spearman test. A p value of less than 0.05 was considered statistically significant. The software used was Statistica (1999 edition, version 5.5; Statsoft, Tulsa, Okla., USA). (Table 1) . Age, sex, triglycerides, and diastolic blood pressure were similar in the three groups. Duration of disease, metabolic control and BMI did not differ between the two patient groups. Systolic blood pressure and urinary albumin excretion were higher among patients with microangiopathy compared with the control subjects (p<0.05 for both), but were not significantly different between patients without complications and the control subjects.
Results
Characteristics and biochemical analyses
Plasma concentrations of sP-selectin were higher in patients with microangiopathy compared with the control subjects (p<0.01) and to patients without microangiopathy (p<0.05), but were not significantly different between patients without microangiopathy and the control subjects.
Serum concentrations of sCD40L were increased in patients with microangiopathy compared with the control subjects (p<0.05), but did not differ between patients without microangiopathy and the control subjects. CRP was increased in patients with microangiopathy compared with the control subjects (p<0.01), but did not differ between patients without microangiopathy to the control subjects.
sE-selectin was increased among patients with microangiopathy (p=0.02; compared with the control subjects), but did not differ between patient groups, or between patients without microangiopathy and the control subjects. von Willebrand factor antigen did not differ between the three groups.
Monocyte counts were higher in patients with microangiopathy compared with the control subjects (p<0.05). Plasma concentrations of prothrombin fragment F1+2 (a marker of thrombin generation), fibrinogen and urinary 11-dehydro-thromboxane B 2 excretion did not differ between the groups.
Platelet P-selectin expression (Fig. 1) . Platelet P-selectin expression in unstimulated samples did not differ between the groups. Thrombin induced platelet Pselectin expression was significantly enhanced in patients with microangiopathy compared with the control subjects (p<0.01), as well as with patients without angiopathy (p<0.05). Platelet P-selectin expression responses to thrombin did not differ between patients without microangiopathy and the control subjects. Responses to ADP (1 µmol/l) did not differ between the three groups.
Correlations. Serum concentrations of sCD40L were correlated with thrombin-induced P-selectin expression (R=0.30; p<0.05; all subjects and R=0.46; p<0.05; patients with microangiopathy), but not with sP-selectin.
Discussion
Our study shows that mild microangiopathy (i.e. early stage retinopathy) in Type 1 diabetes is associated with platelet hyperactivity, even though the patients were metabolically well controlled. Thrombin induced platelet P-selectin expression was enhanced and soluble P-selectin in plasma was increased in patients with microangiopathy compared with healthy control subjects. Furthermore, we found signs of enhanced inflammatory activity and endothelial dysfunction with higher concentrations of sCD40L, CRP and sE-selectin in serum among the patients with microangiopathy.
The findings that soluble P-selectin was increased and platelet P-selectin expression was enhanced among Type 1 diabetic patients with microvascular complications, but not in patients without complications, indicate that platelet activation is related to the presence of microangiopathy, rather than to diabetes per se, and that diabetic microangiopathy is associated with accelerated hemostasis. Soluble CD40L was increased among our patients with microangiopathy compared with the control subjects. It has been shown that platelets release CD40L upon thrombin stimulation in vitro and during thrombus formation in vivo [5] . Accordingly, in the present study, serum sCD40L concentrations correlated with the thrombin induced P-selectin expression. Recently, increased concentrations of sCD40L were reported in patients with acute coronary syndromes, and concentrations above 5.0 µg/l indicated an increased risk for cardiac events [6] . Notably, our Type 1 diabetic patients with microangiopathy had a mean value of 5.3 µg/l for sCD40L, i.e. in the same range as high risk patients with coronary artery disease.
Both platelet derived P-selectin and CD40L may activate endothelial cells and leukocytes [4, 5] . Thus, platelet activation is not only involved in hemostasis, but could initiate a persistent inflammatory response of the vessel wall, inducing a vicious circle of endothelial perturbation and secondary platelet activation. Our finding of increased circulating CRP among patients with microangiopathy supports the presence of ongoing low-grade chronic inflammation in the Type 1 diabetic vasculature [8] and indicates a high risk for developing macrovascular complications [9] .
We found no differences in von Willebrand factor antigen in plasma between groups, which could indicate that endothelial function was only mildly disturbed in the diabetic patients investigated. However, the increase in sE-selectin in our study show that there is an early endothelial perturbation in Type 1 diabetic patients with microangiopathy. Our data are in agreement with the suggestion that von Willebrand factor is a less sensitive marker for endothelial dysfunction than sE-selectin.
In conclusion, our study shows that Type 1 diabetic patients with microvascular complications and good metabolic control have hyper-reactive platelets, as well as signs of endothelial-cell activation and lowgrade chronic inflammation. Taken together, the present and a previous study suggest that generalised platelet activation does not precede the development of microvascular complications [10] , but this needs to be proven in a longitudinal study. However, our study indicates that Type 1 diabetic patients with early stages of microangiopathy are at increased risk for developing cardiovascular disease.
